Trial Profile
A Multicenter Randomized, Double-blind, Placebo-controlled Trial of Famitinib in Patients With Advanced Colorectal Adenocarcinoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Dec 2020
Price :
$35
*
At a glance
- Drugs Famitinib (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms FACT
- Sponsors Jiangsu Hengrui Medicine Co.
- 21 Dec 2020 Status changed from active, no longer recruiting to completed.
- 16 Apr 2018 Planned End Date changed from 31 Dec 2017 to 1 Jun 2019.
- 16 Apr 2018 Planned primary completion date changed from 30 Nov 2017 to 1 Nov 2018.